SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics disclosed the end of Dr

Tango Therapeutics, Inc. · 8-K filed Aug 6, 2026 at 17:30 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Aug 6, 2026 at 17:30 ET

Tango Therapeutics disclosed the end of Dr. Barbara Weber's employment as Executive Chair, effective August 3, 2026, with her resignation from all officer and board positions. The departure is not due to any disagreement with the company, and a separation agreement with standard severance benefits has been offered. This is a routine executive transition with no financial impact disclosed, making it a neutral event for the stock.

  • Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026.
  • Dr. Weber resigned from all officer and board member positions, including the board of directors.
  • The resignation was not a result of any disagreement with the company.
  • The company offered severance pay through December 31, 2026, COBRA reimbursement, and accelerated vesting of certain equity awards.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access